Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment

PALATIN TECHNOLOGIES INC

Fosun dispensed first Vyleesi prescription in Hainan Province, China.
Kwangdong completed Phase 3 enrollment: 193 patients enrolled, 180 completed (93%).
Data from Korea trial expected by year end; potential MFDS submission in H1 2024.
Palatin eligible for up to $92.5M in milestones from Fosun plus royalties; $3M milestone from Kwangdong.
Vyleesi is only FDA-approved as-needed HSDD treatment; Palatin reported six consecutive quarters of double-digit prescription growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.